Abstract: A ventricular catheter assembly including a proximal catheter and a cooperating cranial cover. The cranial cover includes a base plate having an opening aligned with a burr hole in the skull of a person. A guide extends upwardly from the base plate and receives the proximal catheter.

Abstract: Methods and compositions disclosed herein generally relate to determination of susceptibility to eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto and the diagnosis, treatment, and/or management of eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto. Embodiments of the invention relate to the association between genes and specific polymorphisms of genes with eosinophilic esophagitis. Embodiments of the invention can be used to determine and manage patient risk factors for development of eosinophilic esophagitis; this determination can then be used to diagnose eosinophilic esophagitis and to treat a patient diagnosed with eosinophilic esophagitis.

Abstract: Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of eosinophil lineage-committed progenitor (EoP) is elevated in a blood sample obtained from a subject, diagnosing the subject with active EoE when an EoP level in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the EoP level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE. Kits related to same are also disclosed.

Abstract: One or more techniques and/or systems are disclosed for a gastrojejunostomy tube (G-J tube) with a replaceable balloon portion. An example G-J tube can comprise a connection point that is appropriately disposed distally from the balloon portion. The connection can be used to detach a proximal portion from a distal portion of the G-J tube; and a replacement proximal portion can be attached, and the G-J tube can be moved to the desired location. The example G-J tube can comprise a jejunal tube, a gastric tube, and a balloon tube, respectively sized to dispose the distal opening in an appropriate location in the target patient. The proximal portion can comprise at least the balloon tube, the port of the gastric tube, and the port of the jejunal tube.

Abstract: A frequency encoded source imaging system includes an EEG or MEG sensor array and a processing system for analyzing the signals from the sensor array in at least two different frequency bands, where the analysis is localized with respect to a three-dimensional grid corresponding to the portion of the human body.

Abstract: Disclosed are methods for identifying patients at increased risk of developing disseminated staphylococcal infection, which includes the steps of determining that the patient has a mutation in one or more genes selected from a MPDZ network gene, a CGNL1 network gene, a PRKRIR network gene, a MED26 network gene, a tight junction protein gene, or an immune modulator gene; and treating the patient for disseminated staphylococcal infection. Also disclosed are solid substrates and/or assays useful for carrying out the disclosed methods.

Abstract: The methods disclosed herein relate to an improved tool incorporating platelet count into a multi-biomarker based outcome risk stratification model for evaluating mortality risk in pediatric patients having sepsis. The methods described here are useful for treating sepsis, for point of care clinical decision support, for stratifying septic shock patients based on baseline mortality risk, and for clinical trial design, among other uses.

Abstract: Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPAR? agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.

Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

Abstract: An MR loop coil design incorporates a balun into the loop coil. With this approach, some components of the coil may be simultaneously part of the imaging coil and the balun. Further, with this approach the number of components used to build an MR coil may be reduced, which may result in a reduction in cost, weight and size. This MR loop coil design may also be used to build phased array coils from the smaller loop size. Such an approach may use small feeder circuit boards oriented generally perpendicular to the coil elements to reduce interactions between the feeder boards and the coils. Such feeder boards may also be made smaller than conventional feeder circuits because the integrated balun coil design may reduce the number of components needed to create balanced coils in the array.

Abstract: Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.

Abstract: Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto.

Abstract: A method for assessing a neuropsychiatric condition (such as, but not limited to, a risk that a subject may attempt to commit suicide or repeat an attempt to commit suicide, a risk that terminally ill patient is not being care-for or treated according to the patient's true wishes, a risk that a subject may perform or repeat a criminal act and/or a harmful act, a risk of the subject having a psychiatric illness, and/or a risk of a subject feigning a psychiatric illness) may include a plurality of steps. A step may include receiving biomarker data associated from an analysis of the subject's biological sample and a step of receiving thought-marker data obtained pertaining to one or more of the subject's recorded thoughts, spoken words, transcribed speech, and writings. A step may include generating a biomarker score associated with the neuropsychiatric condition from the biomarker data.

Abstract: A ventricular catheter assembly including a proximal catheter and a cooperating cranial cover. The cranial cover includes a base plate having an opening aligned with a burr hole in the skull of a person. A guide extends upwardly from the base plate and receives the proximal catheter.

Abstract: Disclosed are methods of inducing formation of a gastric cells and/or a gastric tissue, such as in the form of a gastric organoid. The formation of gastric cells and/or tissue may be carried out by the activating and/or inhibiting of one or more signaling pathways within a precursor cell. Also disclosed are methods for using the disclosed gastric cells, gastric tissues, and/or gastric organoids derived from precursor cells.

Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).

Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.

Abstract: A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome.

Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof. The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.

Abstract: Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increasing a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention also relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia or ?-thalassemia.